Yahoo · Sep 28, 2026
ORYZON Receives European Medicines Agency Approval to Initiate the HOPE-2 Phase II Study of Vafidemstat for the Treatment of Phelan-McDermid Syndrome (PMS)
PMS is a severely disabling genetic disorder related to autismU.S. prevalence is estimated at approximately 1 in 7,300 people HOPE-2 is partially funded through Oryzon’s VANDAM project under Med4Cure, an Important Project of Common European Interest (IPCEI) on HealthThe study is being advanced in collaboration with the Spanish Phelan–McDermid Syndrome Association MADRID and CAMBRIDGE, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage
